Author: Leaker, Brian R.; Singh, Dave; Lindgren, Sam; Almqvist, Gun; Eriksson, Leif; Young, Barbara; O’Connor, Brian
Title: Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study Document date: 2019_12_19
ID: 15e043uf_4
Snippet: In this study, AZD8848 was administered intranasally to minimise any risk of local inflammatory effects in the lungs and to further reduce the risk of systemic activity. Early murine studies showed localised inflammatory effects in the lungs at high doses, with partial resolution on cessation and with complete resolution at lower doses. Other studies had demonstrated efficacy with both inhaled and intranasal administration and so, supported by ot.....
Document: In this study, AZD8848 was administered intranasally to minimise any risk of local inflammatory effects in the lungs and to further reduce the risk of systemic activity. Early murine studies showed localised inflammatory effects in the lungs at high doses, with partial resolution on cessation and with complete resolution at lower doses. Other studies had demonstrated efficacy with both inhaled and intranasal administration and so, supported by other evidence for an immunological linkage between upper and lower respiratory tract in manthe 'united airways hypothesis [20] [21] [22] clinical development of AZD8848 became focused on intranasal administration.
Search related documents:
Co phrase search for related documents- clinical development and intranasal administration: 1, 2
- clinical development and low dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- clinical development and respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
- clinical development and systemic activity: 1
- complete resolution and high dose: 1, 2, 3, 4, 5, 6, 7, 8
- complete resolution and inflammatory effect: 1
- complete resolution and low dose: 1, 2, 3
- complete resolution and partial resolution: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- complete resolution and respiratory tract: 1, 2, 3, 4, 5, 6
- early murine study and murine study: 1
- high dose and inflammatory effect: 1, 2, 3, 4, 5, 6, 7, 8
- high dose and intranasal administration: 1, 2, 3, 4, 5, 6
- high dose and low dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- high dose and murine study: 1, 2
- high dose and partial resolution: 1
- high dose and respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
- high dose and systemic activity: 1, 2
- inflammatory effect and intranasal administration: 1
- inflammatory effect and low dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Co phrase search for related documents, hyperlinks ordered by date